Latest Cancer News

Palbociclib/Letrozole Improves Outcomes of Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer (02-27-2015)
The results of the phase II PALOMA-1/TRIO-18 trial were recently reported in The Lancet Oncology and suggest that the addition of Ibrance® (palbociclib) to Femara® (letrozole) delayed the time to cancer... Continue Reading

FDA Grants Breakthrough Therapy Designation for MPDL3280A, an anti-PDL1 Investigational Cancer Immunotherapy for Non-Small Cell Lung Cancer (02-26-2015)
The investigational cancer immunotherapy MPDL3280A (anti-PDL1) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). The designation was granted for the treatment... Continue Reading

Farydak® Approval Provides Another Treatment Option for Patients With Multiple Myeloma (02-25-2015)
Novartis announced today that the US Food and Drug Administration (FDA) has approved Farydak® (panobinostat) in combination with Velcade® and dexamethasone for the treatment of patients with multiple... Continue Reading

More Cancer News

Locations

COLCHESTER
Vermont Center for Cancer Medicine and Blood Disorders, Inc.
792 College Parkway, Suite 207
Colchester, Vermont   05446
TEL: (802) 655-3400
FAX: (802) 655-9170

ST ALBANS
Vermont Center for Cancer Medicine and Blood Disorders, Inc.
4 Crest Road,
St. Albans, VT 05478
TEL: (802) 524-0537
FAX: (802) 524-0538

MIDDLEBURY
Vermont Center for Cancer Medicine and Blood Disorders, Inc.
110 Porter Drive,
Middlebury, VT 05753
TEL: (802) 388-8977
FAX: (802) 388-8976